Yuval founded dbMotion Ltd., in 2004 and was its Chairman and CEO until acquired by Allscripts Healthcare, a leading US EMR company, in 2013. Prior to forming dbMotion, Yuval was involved in several startups in the Boston area and held various positions ranging from CTO, EVP and Chairman. Yuval was president of the Customer Experience Management division of Nice Systems and Vice President of
Enterprise Storage Development at EMC Corporation in Boston, Massachusetts. Yuval holds 82 U.S. and European patents in storage and networking. He has a bachelor’s degree in Electrical Engineering from the Technion – Israel Institute of Technology.

Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo.
For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.

Davidi was the VP Product Management, Population Health in Allscripts where he managed the product life cycle from strategic planning and product roadmap to tactical activities, specifying and prioritizing market requirements for the Population Health products. Prior to Allscripts, he was the VP Professional Services for dbMotion Ltd., managed the company enterprise-wide projects in North America,
planning and implementation of dbMotion technologies at customer sites, developing product assimilation methodologies and providing the technical focal point for system integration, customer support and training. He has a BSc degree in Industrial Engineering and MBA degree from the Ben Gurion University in Israel

Josh has responsibility for the strategy, implementation, and growth of the US market for DayTwo.
Since joining the leadership team in 2017, Josh has developed the company’s US strategy, recruited and staffed the US team to support and serve consumers, providers, and employers.
Prior to DayTwo, Josh was CEO of Keas (acquired by Welltok), a health benefits solution for employers that catalyzed employee engagement to utilize healthcare benefits, CRO for YouSendIt (acquired by Western Digital), and Chief Strategy & Revenue Officer for TicketsNow (acquired by Ticketmaster). Prior to TicketsNow, Josh spent 10 years marketing to consumers online at AOL, as the General Manager of eCommerce.
Originally from Boston, Massachusetts, Josh has lived in New York, Illinois, and Virginia. He currently resides in California with his wife and three small children, coaches special Olympics and serves on the investment and audit committees as a Trustee of the Presbyterian Pension Fund.

Amir oversees DayTwo’s commercial activity in international markets.
Amir brings a wide range of leadership experience in building and managing commercial teams that drive rapid growth in international markets. Before Joining DayTwo, Amir served as Executive VP of Business Development at Signals Analytics, a technology-driven, Saas company that is funded by Sequoia Capital, where he played a key role penetrating US and European
markets, dramatically expanding the global customer base to over 50 Fortune 1000 companies.
Before joining Signals, Amir was a Co-Founder and Managing Partner at Arazim Agro, an Israeli agritech company. He served as an Intelligence Officer in the Israeli Air Force and as Assistant to the Israeli Defense Attache in Washington DC. Amir holds an MBA from Ben Gurion University.

David Sayag led Gett R&D, focusing on the entire value chain, from user and driver experience to enterprise-class, large-scale infrastructure. David has 24 years of mobile, software, networking and product experience, serving at executive R&D and product management positions in Gett, 3Com, Sheer Networks (now Cisco), ICQ and as founder at Enure Networks.

Eran is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in the area of Computational and Syste ms biology. His research focuses on studying the relationship between nutrition, health and gut microbes in human individuals.
Prof. Segal published over 110 publications, and received several awards and honors for his work, including the EMBO young investigator award, the Michael Bruno award, and the Overton prize, awarded annually by the International Society for Bioinformatics (ICSB) to one scientist for outstanding accomplishments in the field of computational biology. He was recently elected as an EMBO member and as a member of the young Israeli academy of science.
Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York. Prof. Segal was awarded a B.Sc. in Computer Science summa cum laude in 1998, from Tel-Aviv University, and a PhD. in Computer Science and Genetics in 2004, from Stanford University.

Eran is a Professor leading a research group at the Immunology Department of the Weizmann Institute of Science. His group focuses on deciphering the molecular basis of host-microbiome interactions and their effects on health and disease, with a goal of personalizing medicine and nutrition.
Prof. Elinav published over 110 publications, and received several awards for his work, including the 2013 Alon prize, and the 2015 Rappaport prize, awarded annually to one scientist for outstanding accomplishments in the field of biomedical research.
Before joining the Weizmann Institute, Prof. Elinav held an independent research position as a physician-Scientist at the Institute for Gastroenterology and Liver disease at the Tel Aviv Sourasky Medical Center. Prof. Elinav completed his medical doctor’s (MD) degree at the Hebrew University of Jerusalem Hadassah Medical Center summa cum laude, followed by a clinical internship, residency in internal medicine, and a clinical and research position at the Tel Aviv Medical Center Gastroenterology institute. He received a PhD in immunology from the Weizmann Institute of Science, followed by a postdoctoral fellowship at Yale University School of Medicine.

Dariush Mozaffarian is a cardiologist, Dean and Jean Mayer Professor at the Tufts Friedman School of Nutrition Science and Policy, and Professor of Medicine at Tufts Medical School. As one of the top nutrition institutions in the world, the Friedman School’s mission is to produce trusted science, future leaders, and real-world impact. Dr. Mozaffarian has authored nearly 400 scientific publications on dietary priorities for obesity, diabetes, and cardiovascular diseases, and on evidence-based policy approaches to reduce these burdens in the US and globally. He has served in numerous advisory roles including for the US and Canadian governments, American Heart Association, World Health Organization, and United Nations. His work has been featured in a wide array of media outlets including the New York Times, Washington Post, Wall Street Journal, National Public Radio, and Time Magazine. In 2016, Thomson Reuters named him as one of the World’s Most Influential Scientific Minds.

Dr. Mozaffarian received a BS in biological sciences at Stanford (Phi Beta Kappa), MD at Columbia (Alpha Omega Alpha), residency training in internal medicine at Stanford, and fellowship training in cardiovascular medicine at the University of Washington. He also received an MPH from the University of Washington and a Doctorate in Public Health from Harvard. Before being appointed as Dean at Tufts in 2014, Dr. Mozaffarian was at Harvard Medical School and Harvard School of Public Health for a decade and clinically active in cardiology at Brigham and Women’s Hospital. He is married, has three children, and actively trains as a Third Degree Black Belt in Taekwondo.

The Friedman School pursues cutting-edge research, education, and public impact across five Divisions, a cross-divisional Center, and multiple academic programs. Areas of focus range from cell to society, including: molecular nutrition, human metabolism and clinical trials, nutrition data science, behavior change, community and organizational interventions, communication and media, agriculture, food systems, and sustainability, hunger and food security, humanitarian crisis, and food policy and economics. Friedman School graduates are leaders in academia, US and international government, policy, advocacy, industry, public health, community service, and entrepreneurship. The School’s unique breadth, engagement with the world, and entrepreneurial spirit make it a leading institution for nutrition education, research, and public impact.

Dr. Krauss is Senior Scientist and Director of Atherosclerosis Research at Children’s Hospital Oakland Research Institute, Adjunct Professor of Medicine at UCSF, and Adjunct Professor of Nutritional Sciences at UC Berkeley. He received his undergraduate and medical degrees from Harvard University with honors and served his internship and residency on the Harvard Medical Service of Boston City Hospital. He then joined the staff of the National Heart, Lung, and Blood Institute in Bethesda, Maryland, first as Clinical Associate and then as Senior Investigator in the Molecular Disease Branch.

Dr. Krauss is board-certified in internal medicine, endocrinology and metabolism, and is a member of the American Society for Clinical Investigation, a Fellow of the American Society of Nutrition and the American Heart Association (AHA), and a Distinguished Fellow of the International Atherosclerosis Society. He has served on the U.S. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, was the founding chair of the AHA Council on Nutrition, Physical Activity, and Metabolism, and is a National Spokesperson for the AHA.

Dr. Krauss has also served on both the Committee on Dietary Recommended Intakes for Macronutrients and the Committee on Biomarkers of Chronic Disease of the Institute of Medicine of the National Academy of Sciences. He has received numerous awards including the AHA Scientific Councils Distinguished Achievement Award, the Centrum Center For Nutrition Science Award of the American Society for Nutrition, the Distinguished Leader in Insulin Resistance from the International Committee for Insulin Resistance, and the AHA Award of Meritorious Achievement. In addition he has been the Robert I. Levy Lecturer of the AHA, the Edwin Bierman Lecturer for the American Diabetes Association, and the Margaret Albrink Lecturer at West Virginia University School of Medicine.

Dr. Krauss is on the editorial boards of a number of journals, and has been Associate Editor of Obesity, the Journal of Lipid Research, and the Journal of Clinical Lipidology. He has published over 400 research articles and reviews on genetic, dietary, and drug effects on plasma lipoproteins and coronary artery disease. Among his accomplishments is the identification of atherogenic dyslipidemia, a prevalent lipoprotein trait (high triglyceride, low HDL, and increase in small, dense LDL particles) that is associated with risk of cardiovascular disease and type 2 diabetes.

In recent years Dr. Krauss’ work has focused on interactions of genes with dietary and drug treatments that affect metabolic phenotypes and cardiovascular disease risk.

Rob Knight is the founding Director of the Center for Microbiome Innovation and Professor of Pediatrics and Computer Science & Engineering at UC San Diego. Before that, he was Professor of Chemistry & Biochemistry and Computer Science in the BioFrontiers Institute of the University of Colorado at Boulder, and an HHMI Early Career Scientist. He is a Fellow of the American Association for the Advancement of Science and of the American Academy of Microbiology. He received the 2017 Massry Prize for his microbiome research. In 2015 he received the Vilceck Prize in Creative Promise for the Life Sciences. He is the author of “Follow Your Gut: The Enormous Impact of Tiny Microbes” (Simon & Schuster, 2015), coauthor of “Dirt is Good: The Advantage of Germs for Your Child’s Developing Immune System (St. Martin’s Press, 2017) and spoke at TED in 2014. His lab has produced many of the software tools and laboratory techniques that enabled high-throughput microbiome science, including the QIIME pipeline (cited over 15,000 times as of this writing) and UniFrac (cited over 8000 times including its web interface). He is co-founder of the Earth Microbiome Project, the American Gut Project, and the company Biota, Inc., which uses DNA from microbes in the subsurface to guide oilfield decisions. His work has linked microbes to a range of health conditions including obesity and inflammatory bowel disease, has enhanced our understanding of microbes in environments ranging from the oceans to the tundra, and made high-throughput sequencing techniques accessible to thousands of researchers around the world. Dr. Knight can be followed on Twitter (@knightlabnews) or on his web site http://knightlab.ucsd.edu/.

Dr. Jack A. Gilbert earned his Ph.D. from Nottingham University, UK, in 2002 and received his postdoctoral training in Canada at Queens University. Subsequently, he returned to the UK in 2005 to work for Plymouth Marine Laboratory as a senior scientist until his move to Argonne National Laboratory and the University of Chicago in 2010. Professor Gilbert was the Director of the Microbiome Center and a Professor of Surgery at the University of Chicago. Currently, Dr. Gilbert is a Professor in the Department of Pediatrics and the Scripps Institution of Oceanography at University of California, San Diego. He is also Group Leader for Microbial Ecology at Argonne National Laboratory, Research Associate at the Field Museum of Natural History, Scientific Fellow at the Marine Biological Laboratory, and the Yeoh Ghim Seng Visiting Professorship in Surgery at the National University of Singapore. Dr. Gilbert uses molecular analysis to test fundamental hypotheses in microbial ecology. He has authored more than 250 peer reviewed publications and book chapters on metagenomics and approaches to ecosystem ecology. He is the founding Editor in Chief of mSystems journal. In 2014, he was recognized on Crain’s Business Chicago’s 40 Under 40 List, and in 2015, he was listed as one of the 50 most influential scientists by Business Insider, and in the Brilliant Ten by Popular Scientist. In 2016, he won the Altemeier Prize from the Surgical Infection Society, and the WH Pierce Prize from the Society for Applied Microbiology for research excellence. He also co-authored “Dirt is Good” published in 2017, a popular science guide to the microbiome and children’s health. He serves on the board of the Genomic Standards Consortium and is the primary investigator for various research ventures, including the Earth Microbiome Project, the Home Microbiome Project, the Gulf Microbial Modeling Project, the Hospital Microbiome Project, and the Chicago River Microbiome Project.